On Tuesday, Eli Lilly and Co (NYSE:LLY) said it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA Corp (NASDAQ:NVDA).
The supercomputer is the world’s first NVIDIA DGX SuperPOD with DGX B300 systems.
Several proprietary AI models will be available on Lilly TuneLab, a collaborative federated AI/ML drug discovery platform.
TuneLab will continue evolving its suite of available models, including adding workflows that incorporate select NVIDIA Clara open-source models.
According to Lilly’s sustainability commitments, including carbon neutrality by 2030, the supercomputer will run on 100% renewable electricity within existing Lilly facilities and use Lilly’s existing chilled water infrastructure for liquid cooling.
Also Read: Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections
On Wednesday, Eli Lilly and Walmart Inc. (NYSE:WMT) collaborated to expand access to direct-to-consumer pricing for Zepbound (tirzepatide) single-dose vials available through LillyDirect.
Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
LillyDirect’s direct-to-consumer or self-pay pricing offers a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity.
Zepbound single-dose vials will be available in all approved strengths, with the lowest dose starting at $349 per month with self-pay.
Patients with valid, on-label prescriptions can access Zepbound vials directly without insurance.
- $499 monthly for all other doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg).
- To access the $499 monthly price for doses above 5 mg, patients must meet the requirements of the Zepbound Self-Pay Journey Program.
In the second quarter of 2025, LillyDirect’s self-pay option experienced rapid growth with approximately 35% of new Zepbound prescriptions fulfilled through LillyDirect.
Price Action: LLY stock is up 0.94% at $827.84 at the last check on Wednesday.
Read Next:
Photo: Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
